Regulatory approval
Published by the Health Service Executive. Approved
Treatment of adult patients with Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.
This is written in the approval document.
Reimbursement
CDS
Citation
Therapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.
Organizations
Biomarkers
Cancer types
Therapies
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| HSE (1) | not BCR::ABL1 | Acute Lymphoblastic Leukemia | Ponatinib | |
| HSE (1) | ABL1 p.T315I, not BCR::ABL1 | Acute Lymphoblastic Leukemia | Ponatinib |
Contributions
| Date | Contributor | Description |
|---|---|---|
| 2024-01-16 | Van Allen lab | Adding HSE approvals for reimbursement to database |
| 2016-12-20 | Health Service Executive | Indication approved for reimbursement. |